clinical trial · NCT07577583
Long-term Follow-up (LTFU) of Participants Who Received Azer-Cel
B-cell Mediated Autoimmune DisordersNo Intervention
brief summary
The main objective of this study is to collect data on the long-term safety of azer-cel, primarily through the capture of clinical events of interest (CEI) for up to 15 years following participation in TG-Azercel -101 study.
started
May 1, 2027
primary completion
Dec 1, 2039
completion
Dec 1, 2039
last updated
Oct 29, 2026
official title
Long-term Follow-up (LTFU) of Study Participants Who Received Azer-Cel, An Allogeneic Chimeric Antigen Receptor T-Cell Product, in a TG Therapeutics, Inc., Clinical Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol